240 related articles for article (PubMed ID: 32569779)
1. MicroRNAs in cancer therapy: Their involvement in oxaliplatin sensitivity/resistance of cancer cells with a focus on colorectal cancer.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Hashemi F; Hashemi F; Samarghandian S; Najafi M
Life Sci; 2020 Sep; 256():117973. PubMed ID: 32569779
[TBL] [Abstract][Full Text] [Related]
2. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Zhu M
Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Hashemi F; Moghadam ER; Owrang M; Hashemi F; Makvandi P; Goharrizi MASB; Najafi M; Khan H
Cell Signal; 2021 Feb; 78():109871. PubMed ID: 33279671
[TBL] [Abstract][Full Text] [Related]
5. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
[TBL] [Abstract][Full Text] [Related]
6. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer.
Qi FF; Yang Y; Zhang H; Chen H
Biomed Pharmacother; 2020 Aug; 128():110329. PubMed ID: 32502843
[TBL] [Abstract][Full Text] [Related]
8. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
9. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
11. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
12. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
13. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
14. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
15. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
16. Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells.
Poel D; Boyd LNC; Beekhof R; Schelfhorst T; Pham TV; Piersma SR; Knol JC; Jimenez CR; Verheul HMW; Buffart TE
Cells; 2019 Sep; 8(9):. PubMed ID: 31546954
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.
Moradi Marjaneh R; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
IUBMB Life; 2019 Oct; 71(10):1428-1441. PubMed ID: 31322820
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
20. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]